Effect Of Metformin On The Prognosis Of Diabetic Patients With Bladder Cancer After Surgery

Objective: To investigate the clinical features associated with non-muscle invasive bladder cancer in patients with combined type 2 diabetes and their prognosis,and to further analyse whether metformin administration has an effect on the progression of recurrence after surgery in patients with non-muscle invasive bladder cancer combined with type 2 diabetes.Methods: Retrospective analysis of clinical data of 207 patients,all of whom were diagnosed with non-muscle invasive bladder cancer from January 2015 to December2018 at the Eagle Mountain Hospital affiliated to the Wanan Medical College,which was divided into 66 patients with non-muscle invasive bladder cancer with combined T2 DM and 141 patients with non-muscle invasive bladder cancer without combined T2 DM during the same period(non-diabetic group),with 26 patients with combined The clinical characteristics between the groups were analysed,and the Kaplan-Meier survival curves were plotted using the spss software and compared with the log The Kaplan-Meier survival curves were plotted using SPSS software and then compared with the Log Rank test to determine whether the differences between the groups were statistically significant in terms of relapse-free survival(RFS)and progression-free survival(PFS).By analysing whether each single factor was statistically significant using the COX proportional risk model,and then conducting a multifactorial analysis of the single factors that were significant or clinically considered to be significant,it was determined whether metformin use and diabetes had any effect on the progression of surgical recurrence in non-muscle invasive bladder cancer.Results: By one-way ANOVA and multiple comparisons,the age of the type 2 diabetic group taking metformin(55.81±16.06)was significantly lower than that of the other two groups,and the difference was statistically significant(P<0.05);the follow-up time of the type 2 diabetic group not taking metformin(36.23±15.54)was significantly lower than that of the other two groups,and the difference was statistically significant(P<0.05).The log rank test and KM survival curve revealed that the RFS in the type 2diabetic group taking metformin was significantly higher than that in the non-diabetic group,and the RFS in the non-diabetic group was significantly higher than that in the type 2 diabetic group not taking metformin,and the differences were statistically significant(P<0.05),and there was no statistically significant difference between the metformin and non-diabetic groups.COX multifactor regression analysis showed that combined diabetes,combined hypertension,tumour >3cm,higher tumour stage and whether metformin was taken affected the postoperative RFS of bladder cancer patients,and combined diabetes,combined hypertension,tumour >3cm and higher tumour stage were associated with shorter RFS of patients.risk factor for the development of progression in bladder cancer patients after surgery,while taking metformin and combined diabetes were not statistically associated with postoperative PFS in bladder cancer patients.Conclusion: Combined diabetes is a risk factor for bladder cancer recurrence.Taking metformin may reduce the risk of postoperative recurrence in patients with bladder cancer combined with diabetes and can improve the prognosis of patients.